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Antitumour effects of retinoids are attributed to their influence on cell proliferation, differentiation, apoptosis and angiogenesis. In our
effort to develop useful agents for breast cancer therapy, we evaluated the effects of four representative retinoic acid metabolism
blocking agents (RAMBAs, VN/14-1, VN/50-1, VN/66-1 and VN/69-1) on growth inhibition of oestrogen receptor positive (ER þve,
MCF-7 and T-47D) and oestrogen receptor negative (ER  ve, MDA-MB-231) human breast cancer cells. Additionally, we
investigated the biological effects/molecular mechanism(s) underlying their growth inhibitory properties as well as their antitumour
efficacies against MCF-7 and MCF-7Ca tumour xenografts in nude mice. We also assessed the effect of combining VN/14-1 and
all-trans-retinoic acid (ATRA) on MCF-7 tumuor xenografts. The ER þve cell lines were more sensitive (IC50 values between 3.0 and
609nM) to the RAMBAs than the ER  ve MDA-MB-231 cell line (IC50¼5.6–24.0mM). Retinoic acid metabolism blocking agents
induced cell differentiation as determined by increased expression of cytokeratin 8/18 and oestrogen receptor-a (ER-a). Similar to
ATRA, they also induced apoptosis via activation of caspase 9. Cell cycle analysis indicated that RAMBAs arrested cells in the G1 and
G2/M phases and caused significant downregulation (480%) of cyclin D1 protein. In vivo, the growth of MCF-7 mammary tumours
was dose-dependently and significantly inhibited (92.6%, Po0.0005) by VN/14-1. The combination of VN/14-1 and ATRA also
inhibited MCF-7 breast tumour growth in vivo (up to 120%) as compared with single agents (Po0.025). VN/14-1 was also very
effective in preventing the formation of MCF-7Ca tumours and it significantly inhibited the growth of established MCF-7Ca tumours,
being as effective as the clinically used aromatase inhibitors, anastrozole and letrozole. Decrease in cyclin D1 and upregulation of
cytokeratins, Bad and Bax with VN/14-1 may be responsible for the efficacy of this compound in inhibiting breast cancer cell growth
in vitro and in vivo. Our results suggest that our RAMBAs, especially VN/14-1 may be useful novel therapy for breast cancer.
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The potential of all-trans-retinoic acid (ATRA) and other retinoids
in prevention and therapy of a number of proliferative diseases
including breast cancer was noted almost 20 years ago (Moon et al,
1985). The ability of ATRA as well as other natural and synthetic
retinoids to modulate a variety of important functions such as cell
growth and differentiation, induction of apoptosis and prevention
of angiogenesis is well documented (Dragnev et al, 2000; Altucci
and Gronemeyer, 2001; Boyle, 2001; Fontana and Rishi, 2002).
4-Hydroxyphenyl retinamide (4-HPR) – a synthetic retinoid – is a
possible therapeutic option for early breast cancer in premeno-
pausal women (Torrisi and Decensi, 2000).
All-trans-retinoic acid is currently being used in the treatment
of acne and psoriasis. It is effective in chemotherapy of acute
promyelocytic leukaemia and also inhibiting the in vivo develop-
ment of carcinogen-induced carcinoma of the breast, bladder,
liver, lung, pancreas, prostate, ovaries and skin (Miller, 1998;
Altucci and Gronemeyer, 2001; Njar et al, 2006a,b). All-trans-
retinoic acid and its isomers exert their action by binding to their
nuclear receptors: retinoic acid receptors (RARs) and retinoid X
receptors (RXRs). Both the receptors have three subtypes a, b and
g that regulate the expression of a variety of genes. These receptors
also heterodimerise with other nuclear steroid receptors that lead
to transcription of various genes.
Although numerous studies have shown the anticancer effect of
ATRA against different neoplasms, the clinical use of ATRA has
been thwarted by the emergence of resistance (Wouters et al, 1992;
Van Huesden et al, 2002). Several molecular mechanisms may
underlie ATRA resistance, including (1) downregulated expression
or mutation of RARa or -b receptors (Lin et al, 2000; Tanaka et al,
2004); (2) different levels of expressions of cellular retinoic acid
binding proteins (CRABP I and II) (Arapshian et al, 2004) leading
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sto rapid metabolism of ATRA (Budhu and Noy, 2002); (3)
overexpression of HER2/Grb2/Akt pathway (Mendoza-Gamboa
et al, 2004); and (4) metabolism of ATRA by cytochrome P450
(CYP)-dependent ATRA 4-hydoxylase enzymes namely CYP26
family, CYP2C8 and CYP3A4 (McSorley and Daly, 2000; Marill
et al, 2002; Njar, 2002; Njar et al, 2006a,b). All-trans-retinoic acid
is responsible for inducing the expression of cytochrome P450
enzymes leading to its catabolism. The physiologically most
prominent pathway for ATRA metabolism starts with the
hydroxylation at the C-4 position of the cyclohexenyl ring leading
to the formation of 4-hydroxy-ATRA and other metabolic
by-products. This tightly controlled negative feedback mecha-
nism limits the availability of ATRA and consequently its
biological activity. Therefore, the strategy to increase intracellular
levels of ATRA by inhibition of its metabolism is considered an
innovative approach for cancer therapy. Inhibitors of ATRA
metabolism are also called retinoic acid metabolism blocking
agents (RAMBAs).
Whereas several categories of nonretinoidal RAMBAs have
been reported (reviewed in Njar, 2002; Njar et al, 2006a), only a
few retinoidal RAMBAs developed by our group are known. Our
RAMBAs are also considered to be atypical, because in addition to
being potent inhibitors of ATRA metabolism (able to enhance the
antiproliferative action of ATRA), they also possess intrinsic
potent cancer antiproliferative activities (Njar et al, 2000, 2006a;
Njar, 2002; Patel et al, 2004; Huynh et al, 2006; Belosay et al, 2006).
We have also found that our RAMBAs appear to have different
potencies in different types of human cancer cell lines. For
example, VN/14-1 is a weak inhibitor of several prostate cancer
cells but the compound has been identified as our most potent
RAMBA in several breast cancer cell lines (Patel et al, 2004; Belosay
et al, 2006; Huynh et al, 2006). Here, we present data on growth
inhibition, molecular mechanisms/biological effects and in vivo
antitumour effects of these new RAMBAs against breast cancer cell
lines and tumours. We report that our RAMBAs are capable of
inducing differentiation, apoptosis, affecting the cell cycle
proteins, as well as altering the expression of oestrogen receptor-
a (ER-a) in breast cancer cells. In addition, we have identified VN/
14-1 as a highly potent suppressor of growth of human MCF-7 and
MCF-7Ca tumour xenograft (derived from MCF7Ca cells, that is
human MCF-7 human breast cancer cells stably transfected with
human aromatase gene) in female nude mouse model that is more
effective than either ATRA or 4-HPR. VN/14-1 is also as effective
as clinically used aromatase inhibitors (AIs) and caused preven-
tion of MCF-7Ca tumour formation.
MATERIALS AND METHODS
Material for cell culture
Improved Dulbecco’s modified Eagle’s medium (IMEM), RPMI
1640 medium, OPTI-MEM I (low-serum medium), Dulbecco’s
phosphate-buffered saline (PBS), trypsin/EDTA solution and
penicillin/streptomycin were purchased from GIBCO (Invitrogen
Corporation, Grand Island, NY, USA). Regular fetal bovine serum
(FBS) was from Hyclone (Logan, UT, USA). Tissue culture flasks
(T-25, T-75 and T-150), six-well plates and 24-well plates were
obtained from Corning Incorporated (Corning, NY, USA).
Cell lines
Hormone-dependent/oestrogen receptor positive (ER þve) MCF-
7 cells were a generous gift from Dr Richard Santen (University
of Virginia health system, Charlottesville, VA, USA), whereas
MDA-MB-231 (oestrogen receptor negative (ER –ve)) cells were
purchased from American type cell culture (ATCC). MCF-7 and
MDA-MB-231 cells were cultured in IMEM with glutamine and
phenol red, supplemented with 5% FBS and 1% penicillin–
streptomycin. MCF-7Ca cells were cultured in Dulbeco’s modified
Eagle’s medium supplemented with 5% FBS, 1% penicillin–
streptomycin, 700mgml
 1 G418. Cells were grown as a monolayer
in T75 or T150 tissue culture flasks in a humidified incubator (5%
CO2, 95% air) at 371C. Hormone-dependent/ER þve T47D cells
were purchased from ATCC, and cultured in RPMI 1640 medium
with glutamine, supplemented with 10% FBS and 1% penicillin–
streptomycin. Cells were grown as a monolayer in T75 or T150
tissue culture flasks in a humidified incubator (5% CO2, 95% air)
at 371C.
Chemicals/test compounds
All-trans-retinoic acid was purchased from Sigma Chemical
Company (St Louis, MO, USA) and LKT laboratories Inc. (St Paul,
MN, USA), whereas [11,12-
3H]ATRA was purchased from
Perkin Elmer Life Sciences Inc. (Boston, MA, USA). Retinoic acid
metabolism blocking agents (VN/14-1, VN/50-1, VN/66-1 and VN/
69-1) (Figure 1) were designed and synthesised by us (Njar et al,
2000; Patel et al, 2004). 4-Hydroxyphenyl retinamide (fenretinide)
is available commercially, but was also synthesised in our
laboratory. 4-Hydroxyphenyl retinamide was prepared by a
literature method (Moon et al, 1979), provided spectral and
analytical data as described (Moon et al, 1979).
Antibodies for Western immunoblotting
Antibodies against cytokeratin 8/18 (CK 8/18), E-cadherin and
ER-a were purchased from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA, USA) Antibodies against poly ADP ribose polymerase
(PARP), Cyclin- D1, Caspase-9 and Bad were obtained from Cell
Signaling Technology (Danvers, MA, USA). Antibody for b-actin
was obtained from Calbiochem (San Diego, CA, USA). Secondary
anti-mouse IgG horseradish peroxidase (HRP) conjugate antibody
was purchased from Calbiochem and Bio-Rad. Secondary anti-
rabbit IgG HRP conjugate antibody was purchased from Bio-Rad
as well as from Kirkegaard and Perry laboratories.
Animals and material for in vivo studies
Ovariectomised female athymic nude mice (4–6-week old) used
for tumour xenograft studies were obtained from NCI/FDRC. The
mice were maintained in controlled environment with food and
water ad libitum. Oestrogen pellets (1.7mg per pellet, 90 day
release) were purchased from Innovative Research of America
(Sarasota, FL, USA). Matrigel was purchased from BD Biosciences
(Bedford, MA, USA). All the animal studies were performed
according to the guidelines and approval of the animal care
committee of the University of Maryland School of Medicine,
Baltimore, and were consistent with United Kingdom Coordinating
Committee on Cancer Research guidelines for the welfare of
animals in experimental neoplasia.
Cell growth inhibition assays (MTT colorimetric assay)
These assays were performed as described previously (Patel et al,
2004).
Retinoid receptor binding assays
To determine the IC50 values for each RAMBA, competition
binding experiments were performed as described previously
(Soprano et al, 2000; Zhang et al, 2003). The full-length cDNA
clones for RARa, RARb, RARg and RXRa were cloned into the
prokaryotic expression vector pET29 and recombinant S-Tag
protein for each RAR subtype, and RXR were prepared as
described previously (Tairis et al, 1995; Scafonas et al, 1997).
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concentration of 1.0nM [
3H]-all-trans-RA (1.82–1.92TBqmmol
 1
or 49.2–52.0Cimmol
 1; Dupont (Boston, MA, USA) NEN) for
RARa, RARb and RARg or 1.0nM [
3H]-9-cis-RA (1.74TBqmmol
 1
or 47.2Cimmol
 1; Amersham, Piscataway, NJ, USA) for RXRa and
various concentrations of each RAMBA ranging from 1nM to 1mM.
IC50 values are the concentration of each VN compound that
reduced binding of either [
3H]-all-trans-RA (RARs) or [
3H]-9-
cis-RA (RXRa) by 50%.
Transactivation assays
The ability of each RAMBA to function as a tanscriptional agonist
of RARa, RARb and RARg was determined as described previously
(Tairis et al, 1995; Scafonas et al, 1997; Soprano et al, 2000; Zhang
et al, 2003). Briefly, CV-1 cells were cotransfected with 4mg RAR
subtype (RARa, RARb or RARg) expression vector construct in
pSG5, 4mg RARE-CAT reporter DNA and 1mg pCMV-b-gal DNA.
Twenty-four hours following transfection, the cells were treated
with various concentrations of each RAMBA ranging from
10
 11–10
 5 M along with an ethanol carrier control. Additional
cells were treated with 10
 6 M all-trans-RA for normalisation.
Twenty-four hours later, the cells were harvested and CAT and
b-gal activities were assayed. The EC50 value for each RAMBA
represents the concentration of the compound that results in 50%
of the maximal activity obtained with 10
 6 M all-trans-RA.
Anti-AP1 assay
The ability of each RAMBA to inhibit AP1 activity was determined
using anti-AP1 assays as we have described previously (Soprano
et al, 2000). Briefly, CV-1 cells were cotransfected with 1.5mg RAR
subtype (RARa, RARb and RARg) expression vector construct in
pSG5, 1.5mg AP-1 CAT reporter DNA and 0.5mg pCMV-b-gal
DNA. Four hours following transfection, the cells were treated
with one of the following treatments: ethanol alone, 10
 6 M ATRA,
10
 6 M VN/14-1 or 10
 6 M ATRAþ10
 6 M VN/14-1. Twenty-four
hours later, the cells were harvested and CAT and b-gal activities
were assayed. The percentage of AP-1 activity was calculated using
the ethanol carrier control sample as 100%.
CRABP binding assays
Wild-type full-length cDNAs for mouse CRABPI and CRABPII
were subcloned into the prokaryotic expression vector pRSETB
and transformed into Escherichia coli strain BL21(DE3)pLys (Chen
et al, 1995). Recombinant fusion proteins were prepared essentially
as we have described previously using Ni-NTA resin (Chen et al,
1995). The binding of each RAMBA to CRABPI and CRABPII was
determined by competition binding assays as described previously
(Chen et al, 1995). Briefly, 50nM CRABPI or CRABPII protein
was incubated with 5 or 25nM [
3H]-all-trans-RA (1.82–
1.92TBqmmol
 1 or 49.2–52.0Cimmol
 1; Dupont NEN) (near
the Kd value for CRABPI or CRABPII, respectively) and various
concentrations of each RAMBA ranging from 1 to 500nM.I C 50
values were calculated as described above in the RAR binding
studies.
Determination of apoptosis in breast cancer cells
TUNEL assay using in situ cell death detection kit, alkaline
phosphatase Breast cancer cells (5000 cells per chamber) were
plated on an eight-chamber slide (Nunc lab-Tek chamber slide
system (Fisher Scientific, Pittsburgh, PA, USA). Cells were allowed
to adhere for about 24h and then treated with different
concentrations (1 and 5mM) of ATRA or RAMBAs. The medium
and drug were renewed on day 3. After 6 days of treatment, the
medium was aspirated; cells were washed with PBS and then fixed
with 4% para formaldehyde for about 45min on the slides. After
fixing, the cells were washed with PBS and stored at 41C until
further staining. The cells were then permeabilised using
permeabilisation solution containing 0.1% Triton X-100 in 0.1%
sodium citrate for 2min on ice and then treated with the TUNEL
(terminal deoxynucleotidyl transferase (TdT)-mediated dUTP
nick-end-labelling) reaction mixture containing the enzyme
terminal transferase and the label solution for 60min at 371Ci n
a humidified atmosphere in the dark according to the protocol of
in situ cell death detection kit, AP (Roche Diagnostics, Basel,
Switzerland, Germany). The cells were rinsed with PBS and then
the stained-labelled apoptotic cells were mounted using DAPI
(diamidino-2-phenylindole 2HCl)-glycerol and visualised with a
fluorescent microscope using two filters (1) for TUNEL stained
cells, and (2) for DAPI stained cells, which represents all the cells
(nuclei). Fluorescent microscope model was Nikon, Eclipse E400
and the software was SPOT advanced version 3.5.5 by Diagnostic
Instruments Inc. (Sterling Heights, MI, USA).
Preparation of cell lysates
Breast cancer cells (MCF-7 and T47D) were treated with different
concentration (1, 5 or 10mM) of ATRA or RAMBAs or untreated in
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Figure 1 Structures of retinoic acids, RAMBAs and retinoid 4-HPR.
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sT-75 or T-150 flasks for 6 days. At the end of the treatment, cells
were scrapped and collected by washing with ice-cold PBS in a
centrifuge tube. Cells were centrifuged at 2500r.p.m. for 10min,
the pellet was again washed with ice-cold PBS and centrifuged. The
cell pellet was then suspended in chilled cell lysis buffer (0.1 M
Tris–HCl, 0.5% Triton X-100, protease inhibitor cocktail) and
sonicated on ice for 10–15s. The homogenate was kept on ice for
30min and then centrifuged at 13000r.p.m. for 30min. The
supernatant was used as cell lysate. The cell lysates were stored at
 801C. Protein concentration of the cell lysates was determined
using Bio-Rad protein assay reagents.
Gel electrophoresis and Western immunoblotting
Protein lysates from MCF-7 and T47D cells were subjected to
sodium dodecyl sulphate–polyacrylamide gel electrophoresis
(SDS–PAGE) and immunoblotted for different proteins. Equal
amounts of protein (25–50mg) were subjected to SDS–PAGE at
60V for 3h using the mini PROTEAN3 electrophoresis module
assembly (Bio-Rad, Hercules, CA, USA), and transferred to
nitrocellulose membranes (Hybond ECL, Amersham). Immuno-
detections were carried out using antibodies against CK 8/18
(11 antibody – 1:8000 in 10% milk PBST), E-cadherin (11 antibody
– 1:1000 in 5% milk in TBST) and ER-a (11 antibody – 1:200 in
5% milk PBST) purchased from Santa Cruz Biotechnology Inc.
Antibodies against PARP (11 antibody – 1:1000 in 5% milk TBST),
cyclin- D1 (11 antibody – 1:2000 in 10% milk TBST), caspase-9
(11 antibody – 1:1000 in 10% milk TBST) and BAD (11 antibody –
1:1000 in 5% BSA TBST) were obtained from Cell Signaling
Technology. Antibody for b-actin was obtained from Calbiochem
(CA, USA). Secondary anti-mouse IgG HRP conjugate antibody
was purchased from Calbiochem and Bio-Rad. Secondary anti-
rabbit IgG HRP conjugate antibody was bought from Bio-Rad
as well as from Kirkegaard and Perry laboratories (Gaithersburg,
MD, USA). Immunoreactive bands were visualised using the
enhanced chemiluminescence detection reagents and analysis
system (Amersham Bioscences) according to the manufacturer’s
instructions and quantified by densitometry using ImageQuant
software version 5.
Cell cycle analysis
MCF-7 and T47D cells were plated in T-25 flasks and allowed to
adhere for about 18h. The cells were then synchronised by
growing them in low-serum OPTI-MEM I medium for 2 days. Then
the cells were treated in regular medium for 6 days with different
concentrations (1 and 5mM) of ATRA or RAMBAs with renewal of
drug and media on day 3. After 6-day treatment, the cells were
trypsinised, washed twice with PBS, centrifuged at 2500r.p.m. to
obtain a cell pellet. The cells (about 1–2 10
6) were fixed with
3ml of 70% ethanol (by adding drop-wise and taking care that the
cells are not clumped together). Cells were kept at  201C until
further analysis (at least overnight). Next, cells (B1–2 10
6) were
stained with 1ml of propidium iodide (PI) (50mgml
 1)/RNase
(100mgml
 1) solution and after about half an hour the fluores-
cence of stained nuclei (15000 events) was analysed by flow
cytometry (Becton Dickinson FACScan Instrument and quantifica-
tion by Modfit LT version 3.1 software) with excitation wavelength
of 488nm. The percentage of G1, S, G2/M and sub-G1 (apoptotic
cells) in the population of treated and untreated cells were
determined.
In vivo antitumour studies
All the animal studies were performed according to the guidelines
and approval of the Animal Care Committee of the University
of Maryland, School of Medicine. Ovariectomised female
athymic nude 4–6-week-old mice were used. Oestrogen pellets
(Wen et al, 2000; Patel et al, 2004) were implanted in the dorsal
interscapular region of the mice using a trochar to facilitate
tumour growth. Ovariectomised mice were then inoculated
with MCF-7 cells (2 10
6 cells in Matrigel per tumour growth
site) subcutaneously (s.c.) on the right and left flank. Tumour
volumes were measured weekly with calipers. When the tumour
volumes reached 200–300mm
3, the mice were grouped into
control and treatment groups (n¼5) (Yue et al, 1994; Wen et al,
2000; Patel et al, 2004). Tumour volumes were similar in each
group at the start of the treatment. Retinoic acid metabolism
blocking agents were formulated in 0.3% HPC (hydroxy propyl
cellulose). We used doses equivalent to 5, 10 and 20mgkg
 1 of
ATRA, that is 16.5 (VN/14-1), 33.0 (ATRA, VN/14-1, VN/50-1
and 4-HPR) and 66.0mmolkg
 1 (VN/14-1 and VN/66-1), respec-
tively, in 200ml of vehicle s.c. injection, once per day. Compounds
were injected continuously for three days with a drug holiday
of one day after every 3 days of treatment. Twice per week, the
mice were weighed and tumours were measured using a caliper.
Tumour volume was calculated according to the formula 4/3pr1
2r2
(r1or2). The tumour treatment study was continued for 6 weeks.
At the end of 6 weeks, mice were killed and blood plasma, as well
as tumours, were collected, weighed and stored at  801C until
analysis.
The second experiment was similar to that described above, but
consisted of only four groups. When the tumour volume has
reached about 100mm
3, the mice were randomly divided in to
four groups of five mice each. The control group received
vehicle, whereas the other three groups received ATRA
(33.0mmolkg
 1day
 1), VN/14-1 (16.5mmolkg
 1day
 1) or ATRA
(33.0mmolkg
 1day
 1)þVN/14-1 (16.5mmolkg
 1day
 1). These
treatments continued for 36 days and the tumours were measured
and processed as described above.
The third in vivo antitumour experiment was conducted with
MCF-7Ca tumours. MCF-7Ca were provided by Dr S Chen (City of
Hope, Duarte, CA, USA). The tumour xenografts were grown in
mice as described previously (Yue et al, 1994). Subconfluent cells
were scraped into Delbecco’s phosphate-buffered saline, collected
by centrifugation and resuspended in Matrigel (10mgml
 1)a t
2.5 10
7cellsml
 1. Each mouse received s.c. inoculations in two
sites per flank with 100ml of cell suspension. Mice in the tumour
formation prevention group (n¼5) were than injected daily with
androstenedione (100mgday
 1) plus VN/14-1 (20mgkg
 1day
 1)
in the vehicle for the duration of the experiment. The rest of the
mice were injected daily with 100mgday
 1 of androstenedione.
Measurements and treatments began when the tumours reached
approximately 300mm
3, about 6 weeks after cell inoculation.
Mice were assigned to groups for treatment so that there was no
statistically significant difference in tumour volumes among the
groups at the beginning of the treatment. Tumours were measured
and volumes calculated as described above. Mice were than
injected s.c. daily with the indicated agents: 100mg per mouse per
day (5  weekly) plus 10mg per mouse per day (5  weekly) of
letrozole or 200mg per mouse per day (5  weekly) of anastrozole
and 20mgkg
 1day
 1 (5  weekly) of VN/14-1. The doses of
letrozole, anastrozole, androstendione and VN/14-1 used are as
determined previously (Long et al, 2002, 2004; Patel et al, 2004).
The mice were treated for the indicated times, after which they
were killed by decapitation and blood collected. Tumours and uteri
were excised, cleaned, weighed and stored at  801C for additional
analyses.
Statistical analysis
The statistical differences among the groups were analysed using
Student’s t-test on Sigma Plot 2000 software or Mann–Whitney
U-test using GraphPad Prism 4 for tumour statistics. Differences
were considered to be statistically significant when Po0.05.
RAMBAs effective against breast cancer in vitro and in vivo
JB Patel et al
1207
British Journal of Cancer (2007) 96(8), 1204–1215 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sRESULTS
Effects of RAMBAs on MCF-7, T-47D and MDA-MB-231
cell growth
We have recently reported the synthesis, CYP26 inhibitions and
effects of our novel RAMBAs on the growth of human breast and
prostate cancer cell lines (Patel et al, 2004). These inhibitory effects
of our lead RAMBAs (VN/14-1, VN/50-1, VN/66-1 and VN/69-1),
ATRA and 4-HPR (Figure 1) on three breast cancer cells were
further investigated in the present study with similar results. The
data are summarised in Table 1, and reveal that these RAMBAs
potently inhibited the growth of the two ER þve human breast
cancer cell lines (MCF-7 and T-47D) with IC50 values in the
nanomolar range, with the T-47D cell being more sensitive. VN/14-
1 is also a potent inhibitor of proliferation of MCF-7 cells stably
transfected with human aromatase gene (MCF-7Ca) and also of the
ER þve letrozole resistant long-term letrozole cultured breast
cancer cells (Belosay et al, 2006). The ER  ve MDA-MB-231 breast
cancer cells were less sensitive to these agents (Table 1). The
differential growth inhibitory effects of VN/14-1 are represented in
Figure 2. These promising results with the ER þve breast cancer
cells prompted the present study, which examined the molecular
mechanisms/biological effects underlying their growth inhibitory
potencies. It should be stated that some of the procedure used in
this study were identical to those utilised previously (Patel et al,
2004; Huynh et al, 2006). Except where otherwise stated, all cells
were assessed following 6 days of ATRA/RAMBAs treatments. We
point out that several researchers (Bollag et al, 1997; Toma et al,
1997) including us (Patel et al, 2004) have found that induction of
several biochemical pathways in most cancer cell line become
evident only after 6 days of ATRA/retinoid treatment.
Effects of ATRA and RAMBAs on binding to CRABPs and
retinoid receptors (RAR and RXR) and on transcriptional
activation of RAR receptors
The ability of each of the four RAMBAs to bind CRABPs I and II
and nuclear retinoid receptors was examined by competition
bindings assays (Table 2). Only VN/14-1 displayed significant
Table 1 Inhibitory concentrations (IC50 values) of RAMBAs and
reference compounds, ATRA and 4-HPR, on the growth of human breast
cancer cells
Cellular IC50 (nM)
a,b
Compound MCF-7 T47D MDA-MB-231
VN/14-1 493.5 3.0 24000.0
VN/50-1 125.9 9.0 —
VN/66-1 590.5 569.9 5620.0
VN/69-1 609.0 — —
For comparison
ATRA 585.2 8.0 22000.0
4-HPR 147.8 — 1402.0
ATRA¼all-trans-retinoic acid; RAMBAs¼retinoic acid metabolism blocking agents;
4-HPR¼4-hydroxyphenyl retinamide.
aData from Patel et al. (2004).
bThe IC50
values were determined from dose–response curves (by a nonlinear regression
analysis using GraphPad Prism) compiled from at least two independent experiments
and represents the compound concentration (nM) required to inhibit cell proliferation
by 50%; — ¼ not determined.
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Figure 2 The effects of RAMBA VN/14-1 on proliferation of three
human breast cancer cell line. For MCF-7 and T47D cells, 24-well plates
were used and for MDA-MB-231 cells, 96-well plates were used. Cells
(10000 cells per well of a 24-well plate and 1000 cells per well of a 96-well
plate) were plated and allowed to attach for 24h. Cells were treated with
VN/14-1 dissolved in 95% ethanol on day 1 and day 4 and analysed on day
7 by MTT assay using the spectrophotometer (Victor 1420 multi-label
counter, Wallac (Perkin Elmer, Waltham, MA, USA)). For each concentra-
tion of the drug there were triplicate wells (24-well plate) and six wells
(96-well plate) in every individual experiment. The data presented are
mean7s.e.m. for 2–3 experiments. IC50 values were calculated by
nonlinear regression analysis using GraphPad Prism software.
Table 2 Binding activities (IC50 values) and transactivation activities (EC50 values) of RAMBAs to CRABPs, RARs and RXRa
RAMBAs CRAPBI CRABPII RARa RARb RARc RXRa
IC50
a IC50
a IC50
a EC50
a IC50
a EC50 IC50
a EC50 IC50
a
VN/14-1 NB
b NB
b 16 300 200 1500 16 1000 NB
b
VN/50-1 NB
b NB
b NB
c 410000 NB
c 10000 NB
c 410000 NB
b
VN/66-1 NB
b NB
b NB
c 410000 NB
c 10000 NB
c 410000 NB
b
VN/69-1 NB
b NB
b NB
c 410000 NB
c 410000 NB
c 410000 NB
b
For comparison
Kd
a Kd
a Kd
a EC50
a Kd
a EC50
a Kd
a EC50
a Kd
a
ATRA 4 60 2 20 2 20 2 20 ND
9-CRA ND ND ND ND ND ND ND ND 7
CRABPs¼cellular retinoic acid binding proteins; RAMBAs¼retinoic acid metabolism blocking agents; RARs¼retinoic acid receptors; RXRa¼retinoid X receptors-a;
4-HPR¼4-hydroxyphenyl retinamide.
aValues are indicated as nM.
bNB¼No binding up to 500nM.
cNB¼No binding up to 1000nM.N D¼not determined. IC50 values are the
concentration of each VN compound that reduced binding of either [
3H]-all-trans-RA (CRABPs and RARs) or [
3H]-9-cis-RA (RXRa) by 50%. These values were determined
from dose–response curves compiled from at least three independent experiments.The EC50 value for each RAMBA represents the concentration of the compound that results
in 50% of the maximal activity obtained with 10
 6 M all-trans-RA. These were also determined from dose–response curves compiled from at least two independent
experiments. Details of these experiments are described under Materials and Methods.
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sspecific binding to each of the RAR subtypes with IC50 values
ranging from 16nM for both RARa and RARg to 200nM for RARb.
None of the four RAMBAs displayed binding to CRABPI, CRABPII
and RXRa.
We then examined the functional activity of each of the four
RAMBAs in transactivation assays with RARa, RARb and RARg
(Table 2). Again only VN/14-1 induced RAR-dependent transcrip-
tional activity with EC50 values of 300nM for RARa, 1500nM for
RARb and 1000nM for RARg. Since VN/14-1 displayed agonistic
activity with each RAR subtypes, we examined the ability of VN/
14-1 to inhibit AP1 activity. VN/14-1 at a concentration of 10
 6 M
displayed weak anti-AP1 activity reducing AP1-dependent tran-
scription activity when each of the three RAR subtypes were
cotransfected by 20–40%.
Effect of ATRA, 4-HPR and RAMBAs on the expression
levels of CK 8/18 and ER-a in MCF-7 and T47D cells
The effects of these agents on the expression levels of markers
associated with differentiation (CK 8/18 and ER-a) were investi-
gated following established procedures (Jing et al, 1996; Korsching
et al, 2002; Kim and Freeman, 2003; Woelfle et al, 2004). Breast
cancer cells were treated with the indicated concentrations of
ATRA or RAMBAs (VN/14-1, VN/50-1, VN/66-1 and VN/69-1) for
6 days or 4HPR for 4 days with renewal of media and compounds
on day 3. At the end of the treatment, cell lysates were prepared
and the expression of cytoskeletal proteins CK 8/18 were evaluated
by Western immunoblotting. As shown in Figures 3A and B,
expressions of CK 8/18 were increased in both MCF-7 and T47D
cells after treatments with ATRA and RAMBAs. Treatments with 1
and 5mM concentrations of the compounds (ATRA, VN/14-1 and
VN/50-1) increased B2–3–fold the expression of these proteins
as compared with the control. However, no further up-modulation
of theses markers was observed at higher concentrations of the
RAMBAs. Unexpectedly, VN/66-1 and VN/69-1 caused down-
regulation in the expression of CK 8/18.
An analogous set of experiments was performed to assess the
effects of ATRA (1–10mM) and VN/14-1 (1–10mM) on the level of
ER-a expression in MCF-7 cells. As demonstrated in Figure 4, there
was a significant dose-dependent increase in the expression of
ER-a elicited by both ATRA (from two- to eight-fold) and VN/14-1
(from four- to six-fold). Increase in ER is consistent with more
differentiation. Together, these data suggest that the growth
inhibitory effects of some of our RAMBAs may in part be due to
their ability to induce differentiation in these two breast cancer cell
lines.
Effects of RAMBAs on cell cycle phase distribution and
expression of cyclin D1
To further investigate the causes of the antiproliferative effects of
RAMBAs, with ATRA and 4-HPR as positive controls, cell cycle
analysis was performed on both MCF-7 and T47D cells treated with
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Figure 3 Western immunoblotting analysis of whole-cell lysates of
treated MCF-7 and T47D cells for the expression of CK 8/18: (A) MCF-7
cells were treated with ATRA or RAMBAs for 6 days or 4HPR for 4 days
and then cell lysates were electrophoresed using 10% SDS–PAGE and
subjected to Western blotting. Lane 1: control; lanes 2–4: VN/14-1 (1, 5
and 10mM); lane 5: ATRA (5mM); lane 6: VN/50-1 (5mM); lane 7: VN/66-1
(5mM); lane 8: VN/69-1(5mM); and lane 9: 4-HPR (5mM). (B) T47D cells
were treated with ATRA or RAMBAs (VN/50-1 and VN/14-1) for 6 days
and then cell lysates were electrophoresed using 10% SDS–PAGE and
subjected to Western blotting. Lane 1: control; lane 2: VN/50-1 (1mM); lane
3: VN/50-1 (5mM); lane 4: VN/50-1 (10mM); lanes 5–7: VN/14-1 (1, 5 and
10mM); and lane 8: ATRA (5mM). Numbers below the blot show fold
increase in expression of the protein as analysed by ImageQuant
densitometry analysis. Membranes were stripped and probed for b-actin
to verify equal protein loading. Cytokeratin 8/18 is a 48kDa protein.
Primary antibody CK 8/18 (Santa Cruz Biotechnology) 1:8000 in 10% milk
in PBST for 1h, and secondary antibody (anti-mouse) 1:2000 in 10% milk
in PBST for 1h at room temperature. The experiments were repeated
thrice with similar results.
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Figure 4 Western immunoblotting analysis of whole-cell lysates of
treated MCF-7 cells for the expression of ER-a. MCF-7 cells were treated
with ATRA and VN/14-1 for 6 days and then cell lysates were
electrophoresed using 10% SDS–PAGE and subjected to Western
blotting. Lane 1: control; lanes 2–4: ATRA (1, 5 and 10mM); and lanes
5–7: VN/14-1 (1, 5 and 10mM). Numbers below the blot show fold
increase in expression of the protein as analysed by ImageQuant
densitometry analysis. Membrane was stripped and probed for b-actin to
verify equal protein loading. Primary antibody (Santa Cruz Biotechnology),
1:200 in 5% milk PBST for 2h at RT, secondary antibody (anti-rabbit)
1:3000 in 5% milk PBST for 1h at RT. The experiment was repeated twice
with similar results.
Table 3 Effects of RAMBAs, ATRA and 4-HPR on T47D cell cycle
distribution
Treatment Sub-G1 (%) Go/G1 (%) S (%) G2/M (%)
Control 8.8971.59 74.2873.15 20.4271.02 5.3172.13
VN/14-1 22.3872.95 77.9872.56 1.1871.0 20.8573.75
VN/50-1 21.6771.56 77.7274.54 0.51 21.7875.05
VN/66-1 26.4171.18 80.4470.20 0 19.5770.21
VN/69-1 24.3471.24 78.9970.99 0 21.0170.99
ATRA 17.1274.06 83.8970.96 3.171.3 13.0374.06
4-HPR 30.2576.66 76.9473.47 6.3270.93 16.7574.39
ATRA¼all-trans-retinoic acid; RAMBAs¼retinoic acid metabolism blocking agents;
4-HPR¼4-hydroxyphenyl retinamide. T47D cells were treated with 5mM of ATRA
or RAMBAs for 6 days, or 4-HPR for 4 days. Percentage distribution of cells in each of
the cell cycle phases are expressed as mean7s.e. of at least two independent
experiments.
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sagents for 6 days. As described in Materials and Methods, cells
were stained with PI and cell cycle analysis was performed by flow
cytometry (Toma et al, 1997; Thiantanawat et al, 2003).
Histograms were obtained from the analysis of both cell lines
(data not shown) and the percentages of T47D cells in each cell
cycle phase are presented in Table 3. The cell cycle profiles of the
treated cells were more prominent in the T47D cells, as each
treatment caused a significant increase in the percentage of cells in
the G1 phase and decrease in the percentage of cells in the S phase,
compared with the control. Among all treatments, VN/66-1 and
VN/69-1 caused the greatest suppression (0%) of cells in the S
phase, compared with 20.4% in the untreated control. These
treatments also caused increases in the percentages of cells in the
G2/M phase, but were more prominent in T47D than in the MCF-7
cells (data not shown). Furthermore, we also observed significant
accumulation of cells in the sub-G1 phase of the treated cells,
which may represent cells undergoing apoptosis (Table 3).
Given the well-established involvement of cyclins in the
regulation of cell cycle progression and the previous findings that
cyclin D1 is overexpressed in many cancers and cancer cell lines
(Teixeira and Pratt, 1997; Zhou et al, 1997; Niu et al, 2001), we
investigated the effects of our RAMBAs on the level of cyclin D1
expression. As shown in Figure 5A, ATRA, RAMBAs and 4-HPR,
each significantly decreased cyclin D1 protein expression by
480% in MCF-7 cells as compared with untreated control. This
decrease in the expression of cyclin D1 was also shown to be
dose-dependent following treatment with VN/14-1. Similarly, the
expression of cyclin D1 was significantly downregulated in T47D
cells by treatments with VN/14-1 or VN/50-1 (Figure 5B).
Apoptosis induced by RAMBAs
Because ATRA and most retinoids control cell proliferation via
apoptosis among several other mechanisms in a variety of cancers
(Bollag et al, 1997; Toma et al, 1997; Kotake-Nara et al, 2002;
Afonja et al, 2004; Simeone and Tari, 2004) and also because of the
cell cycle analysis data that suggests accumulation of cell in the
sub-G phase, the apoptotic potential of our RAMBAs was
evaluated. Retinoic acid metabolism blocking agents-induced
apoptosis in MCF-7 and T47D cells was examined in three
independent experiments with ATRA and 4-HPR as positive
controls. First, TUNEL assays, involving a fluorescent DNA-
binding dye, DAPI (Gavrieli et al, 1992; Thiantanawat et al, 2003)
were used to study the morphology of dying cells following
treatment with 5mM RAMBAs, ATRA or 4-HPR for 6 days. Cells
undergoing apoptosis displayed the typical morphologic feature of
apoptotic cells with condensed and fragmented nuclei, and in some
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Figure 5 Western blotting of whole-cell lysates of treated MCF-7 and
T47D cells for the expression of Cyclin D1. (A) MCF-7 cells were treated
with ATRA or RAMBAs for 6 days or 4HPR for 4 days and then cell lysates
were electrophoresed using 15% SDS–PAGE and subjected to Western
blotting. Lane 1: control; lanes 2–4: VN/14-1 (1, 5 and 10mM); lane 5:
ATRA (5mM); lane 6: VN/50-1 (5mM); lane 7: VN/66-1 (5mM); lane 8:
VN/69-1(5mM); and lane 9: 4-HPR (5mM). (B) T47D cells were treated
with VN/50-1 and VN/14-1 for 6 days and then cell lysates were
electrophoresed using 15% SDS–PAGE and subjected to Western
blotting. Lane 1: control; lanes 2–4: VN/50-1 (1, 5 and 10mM); and lanes
5–7: VN/14-1 (1, 5 and 10mM). Numbers below the blot show fold
decrease in expression of the protein as analysed by ImageQuant
densitometry analysis. Membranes were stripped and probed for b-actin
to verify equal protein loading. Primary antibody (Cell Signaling
Technology) 1:2000 in 10% milk TBST overnight at 41C and secondary
antibody (anti-rabbit) 1:2000 in 10% milk TBST for 1h at RT. The
experiments were repeated twice with similar results.
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Figure 6 Graphs showing apoptosis induced in (A) MCF-7 and (B)
T47D cells as determined by TUNEL. (A) MCF-7 cells and (B) T47D cells
(4 10
4)/ well were plated in eight-well slide and treated with 5mM of
ATRA, RAMBAs and 4-HPR for 6 days (see Materials and Methods for
details). TUNEL-stained apoptotic cells were counted against the DAPI
stained cells to obtain percentage apoptosis. The experiments were
repeated thrice with similar results. Error bars show s.e.m of three different
fields of treated cells, statistically significant *Po0.01 and **Po0.001 vs
control.
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scases, membrane blebbing (data not shown). Quantifications of
apoptosis caused by the various agents are presented in Figure 6A
and B. Following treatment with ATRA and RAMBAs, induction
of apoptosis was 8–13% in MCF-7 cells (Po0.01) and 9–17% in
T47D cells (Po0.01) as compared with control which had about
1.5% apoptosis. However, 4HPR caused the most induction of
apoptosis in both the cell lines (20–25%; Po0.001 vs control).
These results strongly suggest that our RAMBAs possess intrinsic
apoptotic activity.
Proteins involved in RAMBAs-induced apoptosis
To further characterise the apoptosis observed in the RAMBAs-
treated breast cancer cells, we used Western blot analysis to assess
the activation and cleavage of apoptosis-related proteins, including
Bad, caspase 9 and PARP. As VN/14-1 was the most effective of the
RAMBAs, we tested VN/14-1 in comparison to ATRA.
We first investigated the effects of VN/14-1 on the expression of
the pro-apoptotic Bad protein. Both VN/14-1 and ATRA at
concentrations of 1, 5 and 10mM each induced upregulation of
Bad protein by about two-fold, but there was no significant dose-
dependent effect (Figure 7A). The possible involvement of Bad
implies that induction of apoptosis by these treatments may be via
the mitochondrial pathway. We therefore examined whether
caspase-9 was activated. This molecule that plays a major role as
an initiator caspase in this pathway was activated (Zou et al, 1999).
As shown in Figure 7B, increased concentration of ATRA and VN/
14-1 treatment caused an increase in the active form (37kDa) and
a decrease in the procaspase form (47kDa). Control cells had a
higher expression of the procaspase-9 (47kDa) than the treated
cells, that is 1 (control) vs 0.4- and 0.3-fold for 5 and 10mM ATRA,
respectively, and 0.4- and 0.7-fold for 5 and 10mM of VN/14-1,
respectively. The active form of caspase-9 was increased by 1.7-
and 1.8-fold with 5 and 10mM of ATRA, respectively, and by 1.7-
and 1.7-fold with 5 and 10mM of VN/14-1, respectively, compared
with untreated control.
Another approach to detect apoptosis was by determining the
proteolysis of PARP, the DNA repair enzyme that can be cleaved
by effector caspases. As shown in Figure 7C, 5mM of ATRA, or VN/
14-1 caused almost two-fold increases in the level of cleaved PARP
(89kDa) as compared with control in MCF-7 cells. Treatment of
T47D cells (Figure 7C) with 1, and 5mM of VN/14-1 caused 6.3- and
7.5-fold increases, respectively, in the levels of cleaved PARP as
compared with the control.
In vivo antitumour study of ATRA, 4-HPR and RAMBAs
To assess the ability of RAMBAs to inhibit tumour growth, we
examined their effects in human MCF-7 breast cancer xenograft
model with ATRA and 4-HPR as positive controls. Female
ovariectomised nude mice bearing established MCF-7 tumour
xenografts (200–300mm
3) were grouped so that the mean tumour
volume was similar for each group. They were then treated once
daily, 6 days per week for a total of 6 weeks, with vehicle (control),
ATRA (33.0mmolkg
 1day
 1), 4-HPR (33.0mmolkg
 1day
 1), VN/
50-1 (33.0mmolkg
 1day
 1), VN/66-1 (66.0mmolkg
 1day
 1) and
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Figure 7 (A) Western immunoblotting of whole-cell lysates of treated
MCF-7 and T47D cells for the expression of Bad. MCF-7 and T47D cells
were treated with ATRA and VN/14-1 for 6 days and then cell lysates were
electrophoresed using 15% SDS–PAGE and subjected to Western
blotting. Lane 1: control; lanes 2–4: ATRA (1, 5 and 10mM); and lanes
5–7: VN/14-1 (1 5 and 10mM). Numbers below the blot show fold
increase in expression of the protein as analysed by ImageQuant
densitometry analysis. Membranes were stripped and probed for b-actin
to verify equal protein loading. Primary antibody (Cell Signaling
Technology) 1:1000 in 5% BSA TBST overnight at 41C and secondary
antibody (anti-rabbit) 1:2000 for 1h at RT. This experiment was repeated
twice with similar results. (B) Western blot showing activation of caspase-9
in T47D cells after treatment with ATRA or VN/14-1. T47D cells were
treated with ATRA or VN/14-1 for 6 days and whole-cell lysates were
electrophoresed using 10% SDS–PAGE and subjected to Western
immunoblotting for caspase-9. Treatment with ATRA and VN/14-1
cleaved procaspase-9 to its active form. Lane 1: control; lanes 2–4: ATRA
(1, 5 and 10mM); and lanes 5–7: VN/14-1 (1, 5 and 10mM). Numbers
below the blot show fold increase in the active form of caspase-9 as
compared with control. Membrane was stripped and probed for b-actin to
verify equal amount of protein loading. The primary and secondary
antibodies and their dilutions are as follows: primary antibody (Cell Signaling
Technology), 1:1000 in 10% milk TBST overnight at 41C and secondary
antibody (anti-rabbit) 1:2000 in 10% milk TBST for 1h at RT.
Densitometry analysis was performed by ImageQuant software. This
experiment was repeated twice with similar results. (C) Western
immunoblotting of whole-cell lysates of treated MCF-7 and T47D cells
for the expression of full-length and cleaved PARP. MCF-7 cells were
treated with ATRA and RAMBAs for 6 days and 4-HPR for 4 days and then
cell lysates were electrophoresed using 10% SDS–PAGE and subjected to
Western blotting. Lane 1: control; lanes 2–4: VN/14-1 (1, 5 and 10mM);
lane 5: ATRA (5mM); lane 6: VN/50-1 (5mM); lane 7: VN/66-1 (5mM); lane
8: VN/69-1(5mM); and lane 9: 4-HPR (5mM). T47D cells were treated with
RAMBAs (VN/50-1 and VN/14-1) for 6 days and then cell lysates were
electrophoresed using 10% SDS–PAGE and subjected to Western
blotting. Lane 1: control; lanes 2–4: VN/50-1 (1, 5 and 10mM); lanes 5–
7: VN/14-1 (1, 5 and 10mM). Numbers below the blot show fold increase in
expression of the protein as analysed by ImageQuant densitometry analysis.
Membranes were stripped and probed for b-actin to verify equal protein
loading. Primary antibody (Cell Signaling Technology) 1:1000 in 5% milk
TBST overnight at 41C and secondary antibody (anti-rabbit) 1:2000 for 1h
at RT. The experiments were repeated twice with similar results.
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sthree doses of VN/14-1 (16.5, 33.0 and 66.0mmolkg
 1day
 1).
Tumour sizes were measured twice a week after the start of
treatment. Because treatment with VN/50-1 was very toxic to the
mice, the experiment with this cohort was terminated. As shown in
Figure 8A, treatment with VN/14-1 produced a dose-dependent
inhibition of tumour growth. Indeed, all three doses of VN/14-1,
that is 16.5, 33.0 and 66.0mmolkg
 1day
 1, caused significant
reductions of 66.5% (Po0.01), 79.4% (Po0.001) and 92.6%
(Po0.0005), respectively, in the mean tumour volume compared
with the vehicle control. The effect of VN/14-1
(16.5mmolkg
 1day
 1 equivalent to 5mgkg
 1day
 1 ATRA) was
comparable with the antitumour effect of ATRA or 4-HPR
(33.0mmolkg
 1day
 1). VN/14-1 (33.0 and 66.0mmolkg
 1day
 1
equivalent to 10 and 20mgkg
 1day
 1 of ATRA, respectively)
caused a significant reduction of 45% (Po0.05) and 75.61%
(Po0.005), respectively, in the mean tumour volume compared
with the ATRA group (10mgkg
 1day
 1). The antitumour effect
of VN/66-1 (66.0mmolkg
 1day
 1) was not better than ATRA.
Importantly, except for the VN/50-1-treated group, no significant
changes in animal body weight were observed even at the highest
concentration of VN/14-1 (Figure 8B), suggesting that the growth-
inhibitory effects were tumour specific and that the treatments did
not produce general cytotoxicity in the mice.
It was of interest to determine the effects of combination of
ATRA and VN/14-1 on the growth of MCF-7 tumour xenografts.
Single agents ATRA (33.0mmolkg
 1day
 1) or VN/14-1
(16.5mmolkg
 1day
 1) resulted in a modest tumour growth
inhibition compared with controls (Figure 9). However, the
combination of ATRA and VN/14-1 resulted in a significant super
additive inhibitory effect (up to 120% growth inhibition, as
compared with controls; Po0.005 vs control). This result supports
the hypothesis that RAMBA VN/14-1 is able to enhance the
biological activity of ATRA through the inhibition of ATRA in
vivo. We have demonstrated previously this effect in in vitro breast
and prostate cancer models (Patel et al, 2004; Huynh et al, 2006).
Effects of VN/14-1 compared with clinical AIs on growth of
MCF-7Ca xenografts
Based on our recent findings that VN/14-1 is also a potent AI
(Belosay et al, 2006) and also because of the prominence of AIs
in breast cancer therapy (Brodie et al, 2003), we wished to test
the effects of VN/14-1 head to head with clinically used AIs,
anastrozole or letrozole. As shown in Figure 10, VN/14-1 was as
effective as either anastrozole or letrozole at inhibiting the growth
of established MCF-7Ca tumours. In addition, VN14-1 was
efficacious in preventing the formation of MCF-7Ca tumours
(Figure 10). We also observed that VN/14-1 treatment caused
significant reduction in uterine wet weight (data not shown),
which indicates that VN/14-1 can effectively block the uterotropic
activity of oestrogens produced by peripheral aromatisation of
androstenedione (Goss et al, 2000; Jelovac et al, 2005).
DISCUSSION
We have reported previously that our novel RAMBAs are potent
inhibitors of ATRA metabolism and also potent inhibitors of
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Figure 8 (A) Effect of ATRA, 4HPR or RAMBAs on the growth of
MCF-7 tumour xenograft in ovariectomised female athymic nude mice.
Ovariectomised female athymic nude 4–6-week-old mice were used.
Oestrogen pellets (1.7mg per pellet, 90 day release obtained from
Innovative Research of America) were implanted in the mice using a
trochar to facilitate tumour growth. Mice were then inoculated with MCF-7
cells (2 10
6 cells in Matrigel per tumour growth site) s.c. on the right and
left flank. Tumours were allowed to grow for about 4–5 weeks till they
were of measurable size (200–300mm
3). The mice were then grouped as
control and treatment groups. Twice every week the mice were weighed
and tumours were measured using a caliper. Tumour volume was
calculated according to the formula 4/3pr1
2r2 (r1or2). The tumour
treatment study was continued for 6 weeks. (B) Effect of vehicle, ATRA
4-HPR and RAMBAs on body weight of ovariectomised female nude mice
during the 6-week antitumour study. Mice were weighed twice every week
during the 6-week antitumour study.
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Figure 9 Effects of ATRA or VN/14-1 alone or in combination on the
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mice. Procedure was similar to that described in Figure 8A.
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These results led us to propose that our RAMBAs also possess
intrinsic retinoidal antitumour properties. Here, we have examined
their molecular mechanisms of action, and shown that adminis-
tration of some RAMBAs to nude mice bearing human oestrogen-
dependent MCF-7 or MCF-7Ca breast tumours can effectively
suppress tumour growth at doses that cause no apparent toxicity.
Like ATRA, each of the RAMBAs tested significantly caused up-
modulation (two- to three-fold) of CK 8/18 in both MCF-7 and
T47D breast cancer cell line, which suggest that our RAMBAs are
capable of inducing differentiation in these breast cancer cell lines.
Further support for the putative role of our RAMBAs as
differentiating agents came from the findings that VN/14-1 caused
a dose-dependent up-modulation (from four- to six-fold) of ER-a
protein, another differentiation marker. The ability of these
RAMBAs to induce differentiation in breast cancer cells may be
of significance in light of recent findings which suggest that
downregulated expressions of CK 18 (Korsching et al, 2002;
Woelfle et al, 2004; Schaller and Buhler, 2005) and/or E-cadherin/
ER-a (Nass et al, 2000; Kowalsski et al, 2003) promote progression
of human breast cancer. It should be noted that differentiated
tumour cells exhibit low proliferative and metastatic potential. An
elevation in the expression of cytokeratins indicates a favourable
prognosis and is a useful predictor for overall survival in breast
cancer patients (Korsching et al, 2002). We have also shown that
VN/14-1 binds and activates the RARs (RARa,- b and -g), but the
other RAMBAs do not activate these receptors. Although it has
been suggested that only ligands that activate RARa can induce cell
differentiation, our current results suggest that some of the
RAMBAs are able to induce differentiation via RAR-independent
pathway(s).
VN/14-1 binds (and transactivates) with higher affinity to RARa
and RARg compared with RARb. Concentrations of VN/14-1 that
can activate these two receptors will probably increase the level
of CYP26 (along with other RA-inducible transcripts) in the cell.
The question is how much of the antiproliferative effect of VN/14-1
is mediated by inhibition of CYP26 activity (increase in ATRA-
and RAR-mediated transcription) vs some other mechanism
leading to apoptosis that does not involve RARs.
Several studies have shown that retinoids inhibit proliferation of
various cancers by inducing arrest of cells in a phase of the cell
cycle. We have demonstrated here that our RAMBAs induce
growth inhibition of both MCF-7 and T47D cells by G1 phase
arrest with concomitant decrease of cells in S phase and also
significant accumulation of cells in the sub-G1 phase. In addition,
we also found increased percentage of cells in the G2/M, but this
was consistently higher in the treated T47D cells than in the MCF-7
cells. We also demonstrated that expression of cyclin D1, the
positive regulator of cell cycle progression from G1 to S phase, was
reduced in MCF-7 and T47D cells after 6-day treatment with
RAMBAs (1, 5 and 10mM). This result is in agreement with the cell
cycle analysis, which revealed G1 phase cell arrest.
The ability of ATRA/retinoids to inhibit the growth of cells has
previously been shown to result from their ability to induce
apoptosis in various cancer cells. In the present investigation, a
significant increase in cells in the sub-G1 phase, accounting for
10–20% of the total cell population was detected after exposure to
RAMBAs. Cells in this phase are thought to represent cells that
have undergone apoptosis. TUNEL analysis confirmed that the
RAMBAs did induce a portion of cells (MCF-7 and T47D) to
undergo apoptosis in a dose-dependent fashion.
Apoptosis induced by ATRA and RAMBAs was further
characterised by assessing the activation and cleavage of
apoptosis-related proteins as determined by Western blot analysis.
Treatment of breast cancer cells (MCF-7 and T47D) with RAMBAs
resulted in proteolysis of full-length PARP – the DNA repair
enzyme, which was comparable to ATRA. In T47D cells, VN/14-1
was able to cleave pro-caspase-9 to active caspase-9, an effect
similar to ATRA. However, the involvements of other caspases
were not investigated. VN/14-1 and VN/50-1 also increased the
expression of the pro-apoptotic Bcl-2 family member Bad. Thus,
induction of apoptosis in breast cancer cells by the RAMBAs was
confirmed by several methods. When compared with 4-HPR (a
retinoid known for inducing apoptosis in breast cancer cells)
(Pellegrini et al, 1995; Wu et al, 2001) apoptosis induced by
RAMBAs was less than 4-HPR, but comparable to ATRA. Although
VN/66-1 exhibited less antiproliferative activity, it induced
apoptosis that was comparable to that induced by ATRA. VN/69-
1 was the least effective of the RAMBAs in inducing apoptosis in
both MCF-7 and T47D cells.
The marked effects that our RAMBAs had on cell proliferation
led to an in vivo study. We studied the effects of VN/14-1, VN/50-1,
VN/66-1 and ATRA. VN/50-1 was found to be toxic to the animals
and its antitumour efficacy could not be assessed. Our results show
that on a molar basis, ATRA and 4-HPR were each more effective
in suppressing the growth of established MCF-7 tumours than
VN/66-1, but both agents were each less effective than
VN/14-1. Indeed, we demonstrated that VN/14-1 inhibited MCF-7
tumour growth in a dose-dependent fashion. A dose of
66.0mmolkg
 1day
 1 caused a reduction of 92.6% in the mean
final tumour weight compared with that of tumour-bearing mice
receiving vehicle alone, with no apparent toxicity as there was no
change in body weight of the mice. It was recently reported that
the growth of murine oestrogen-independent TA3-Ha mammary
tumours were significantly inhibited by a non-retinoidal RAMBA,
R116010 (Van Huesden et al, 2002). The study demonstrated the
antitumour efficacy of R116010 in an oestrogen-independent
model of un-established tumours and it is not clear if the agent
is effective against oestrogen-dependent breast tumours. Our
findings that VN/14-1 is efficacious against well-established breast
tumours suggest that the molecule may be a more effective
anticancer RAMBA.
In the present study, we also demonstrated for the first time a
synergistic inhibitory effect of VN/14-1 and ATRA on the growth
of established MCF-7 and MCF-7Ca breast cancer tumour
xenografts in vivo, and also the prevention of MCF-7Ca tumour
formation. Importantly, VN/14-1 was as effective as the clinically
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Figure 10 Effects of VN/14-1 on the formation of MCF-7Ca tumours
and effects of VN/14-1, anastrozole and letrozole on the growth of MCF-
7Ca xenografts in ovariectomised female athymic nude mice. Mice were
inoculated with MCF-7Ca cells as described in Materials and Methods.
Beginning on the following day, androstendione (100mg per mouse per
day) was supplemented by s.c. injection for the duration of the experiment.
For the tumour formation prevention group (n¼5), VN/14-1
(20mgkg
 1day
 1) treatment began from the day after inoculation. For
the other groups (VN/14-1, anastrazole and letrozole), treatment began
after the tumour had reached approximately 300mm
3 following
procedures described in Materials and Methods.
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caused significant reduction in uteri weights. This suggests that
VN/14-1, unlike tamoxifen, may not cause endometrial hyperplasia
in patients.
The growth inhibitory effects of cell lines and tumour xenografts
especially by VN/14-1 appear to be due to its ability to induce
differentiation, apoptosis and cycle arrest. However, in the
antitumour efficacy studies VN/14-1 did not cause any tumour
regressions. The mechanism underlying the lack of tumour
regression is unknown at this time. One possibility is that the
treatment with VN/14-1 results mainly in cytostatic but not
cytotoxic antitumour effect.
In conclusion, our results clearly suggest that our RAMBAs
induce other biochemical pathways in addition to differentiation.
It appears that the molecular mechanisms for the antiproliferative
activities of our RAMBAs in these breast cancer cells include their
ability to induce cell differentiation, apoptosis and effects on cell
cycle. Among the RAMBAs tested, VN/14-1 was shown to be the
most efficacious in both in vitro and in vivo studies. Not only are
RAMBAs effective against established tumours, but may also be
important as differentiating agents in preventing breast cancer.
As most cancers become resistant to agents that act on specific
targets, the development of molecules that act on multiple cellular
targets offer considerable hope for the development of new cancer
therapies. These novel RAMBAs endowed with multiple biological
activities have potential as therapeutics for breast cancer and
possibly other diseases responding to retinoids. Indeed, VN/14-1
has been selected for further preclinical studies. We were recently
awarded an Australian patent (Njar et al, 2005) to protect these
novel and promising anticancer agents and several other patents
are pending.
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